Results 261 to 270 of about 606,093 (296)

Meningococcal conjugate vaccines

Expert Opinion on Biological Therapy, 2005
Disease caused by Neisseria meningitidis is associated with high mortality rates and significant sequelae. Polysaccharide meningococcal vaccines have been available for > 20 years, and have been used in travellers to control outbreaks, and in some countries for adolescents entering college, although they provide only a short duration of immunity and do
openaire   +3 more sources

Meningococcal vaccine in travelers

Current Opinion in Infectious Diseases, 2007
New vaccines to prevent meningococcal disease have been licensed in recent years. It is therefore timely to discuss current vaccine strategies pertinent to international travelers in relation to the changing epidemiology.Serogroup W135 achieved epidemic status in Africa in 2002, and then largely disappeared over a short time period. The year 2006 saw a
openaire   +2 more sources

A half-century of meningococcal vaccines

Vaccine, 2021
The first safe and effective vaccine for the prevention of invasive meningococcal disease was created fifty years ago. The vaccine employed a novel platform, polysaccharide capsular antigen, based on the discovery that anticapsular antibody conferred protective immunity in humans.
openaire   +3 more sources

Meningococcal Vaccines and Vaccine Developments

2003
Despite rapid advances in the diagnosis of bacterial infections and the availability of effective antibiotics, meningococcal disease continues to represent a substantial public health problem for most countries (1-4). Disease usually develops rapidly, is notoriously difficult to distinguish from other febrile illnesses, and generally has a high case ...
openaire   +3 more sources

The Future of Meningococcal Vaccines

Pediatric Health, 2007
The use of vaccines in the prevention of meningococcal disease has demonstrated their success in improving public health globally. Group C conjugate vaccines have significantly reduced the burden of disease in countries with widespread usage. Promising results are available on the candidate group A conjugate vaccine for Africa, which could potentially ...
Paul Balmer, Ray Borrow
openaire   +2 more sources

Meningococcal tetravalent conjugate vaccine

Expert Opinion on Biological Therapy, 2008
Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. Since 1981, a tetravalent meningococcal polysaccharide vaccine has been available in the US but it has been limited to high-risk patients and outbreak settings. In 2005, a tetravalent polysaccharide meningococcal conjugate vaccine (MCV4) was licensed for routine use in the US.
openaire   +3 more sources

Development of meningococcal vaccines

1978
A few years after the discovery of Meningococcus by Weichselbaum in 18871 numerous vaccines were described and tested almost everywhere in the world. Davis2 seems to have been the first to attempt active immunization, in 1907, using meningococcal cultures heated to 60 °C.
openaire   +2 more sources

Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

MMWR Recommendations and Reports, 2020
Jonathan Duffy
exaly  

Meningococcal Disease and Vaccines

Pediatric Annals, 2001
Peter M. Dull, Nancy E. Rosenstein
openaire   +3 more sources

Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors

Epidemiology and Infection, 2020
Sara Viksmoen Watle
exaly